If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
218
results.
Updated on
23/12/2025 [06:52:00]
Results 75 to 100 of 218
Absstract of: MX2025009357A
Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.
Absstract of: EP4663624A1
Provided in the present disclosure is a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, which is an extrahepatic targeted cationic lipid compound with high efficiency and low toxicity. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic or prophylactic agent.
Absstract of: WO2024165949A1
The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.
Absstract of: WO2024165567A1
The present invention relates to anti-mesothelin constructs, such as antigen binding fragments and single-domain antibodies, that specifically bind to mesothelin, irrespective of the presence of MUC16. The invention further relates to the use of anti-mesothelin constructs in diagnostics and in therapeutic field.
Absstract of: EP4663207A1
The present invention relates to a formulation for non-intravenous administration, comprising nanoparticles having a hydrodynamic diameter of 2 to 20 nm and a surface charge ranging from -20 mV to 0 mV, the nanoparticles being adjusted in size and charge by hydration of hydrophilic functional groups exposed on the surface thereof, such that the nanoparticles are not permeated into or drained into blood capillaries at the administration site but are selectively drained into terminal lymphatic vessels, wherein the nanoparticles: (i) are themselves therapeutic agents; and/or (ii) serve as carriers for other therapeutic agents, and wherein the nanoparticles are engineered to provide a drug modality that, upon administration into a tissue site rather than via intravenous injection, is selectively drained into lymphatic vessels, thereby avoiding drainage into blood capillaries and thus prolonging residence time at the administration site.According to the present invention, the nanoparticles with the adjusted hydrodynamic diameter and surface charge are configured to be completely cleared from the administration site within one week after administration without residual accumulation. When designed as a T1 MRI contrast agent, the nanoparticles enable selective imaging of peripheral and/or central lymphatic vessels without venous contamination when administered to perivascular tissue.
Absstract of: AU2024251515A1
The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.
Absstract of: CN121134839A
本发明涉及一种二氧化锰纳米颗粒及其制备方法和应用。所述二氧化锰纳米颗粒的制备方法包括以下步骤：将正硅酸乙酯、浓氨水和无水乙醇混合，搅拌反应，待反应结束后离心收集沉淀，洗涤、得到SiO2纳米种子；并制备得到SiO2微球；乙酸锰溶液和SiO2微球超声混合后，滴加氧化剂，在70‑95℃下搅拌反应2‑4小时，得到MnO2@SiO2核壳颗粒；将MnO2@SiO2核壳透析得到二氧化锰纳米颗粒。本发明通过分步/种子生长法获得粒径在9μm‑11μm的SiO2微球，然后采用“吸附‑原位氧化”法，形成厚度均匀、致密的MnO2壳层。再通过温和刻蚀法得到塌陷率极低、结构稳定二氧化锰纳米颗粒H‑MnO2。
Absstract of: CN121129819A
本发明属于医学技术领域，具体涉及一种酯酶响应性异羟肟酸类HDAC抑制剂二聚体前药、自组装纳米颗粒及其应用。本发明将酯酶响应性连接臂引入形成HDACi二聚体前药，再通过自组装形成纳米颗粒，构建了兼具静脉可注射性和智能释药特性的纳米递送平台，克服游离HDACi因水溶性差无法静脉给药、体内清除快及脱靶毒性高的临床应用瓶颈。
Absstract of: CN121129814A
本发明涉及医药与功能性食品技术领域，具体为一种基于胶原蛋白肽和蛋壳膜肽自组装的姜黄素纳米复合物及其制备方法，纳米复合物由以下组分按质量百分比组成：蛋壳膜肽40%‑60%、I型胶原蛋白肽25%‑40%、II型胶原蛋白肽10%‑20%、姜黄素10%‑20%，所述纳米复合物为核‑壳结构纳米胶束，制备方法包括原料预处理、配制有机溶剂、溶解疏水组分、旋转蒸发成膜、配制亲水肽溶液、水化自组装、纯化处理；本发明可改善姜黄素溶解度与稳定性，提升口服生物利用度；载体为天然肽类，安全且具生物活性，适配医药制剂与功能性食品需求，产业化潜力高。
Absstract of: CN121135905A
本发明公开了一种枸杞中性均一多糖及其制备方法和应用。本发明通过系统结构表征，首次阐明了该多糖NLBPE1为一种以1,5‑α‑L‑阿拉伯糖为桥连单元的非典型阿拉伯半乳聚糖，具有均一的分子量和明确的支链拓扑结构。NLBPE1作为佐剂与抗原共同包载于多种递送系统中(如PLGA纳米粒、脂质体、水凝胶等)形成疫苗组合物，可显著提高疫苗的免疫原性，增强抗原特异性T细胞应答。本发明提供了该多糖作为疫苗佐剂在肿瘤免疫治疗和肿瘤预防中的应用方案，尤其在与免疫检查点抑制剂联合使用时展现出显著的协同抗癌效果。该多糖具有明确结构、良好生物相容性和显著免疫增强活性，具有广泛的肿瘤疫苗佐剂应用前景。
Absstract of: CN121129796A
本发明公开了一种明胶‑丝素蛋白复合载药纳米颗粒，其由明胶和丝素蛋白通过物理交联共组装形成稳定的复合结构，其中丝素蛋白通过β‑折叠结构形成物理交联网络，明胶分布于该网络中。本发明还公开了所述纳米颗粒的制备方法及在制备用于治疗炎症性疾病的药物中的应用。该纳米颗粒无需化学交联剂，具有粒径可控、载药量高、包封率高及MMP‑9酶响应释药特性，具有良好的生物相容性和抗炎效果，可用于炎症性疾病治疗。
Absstract of: AU2024273170A1
Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.
Absstract of: CN121130109A
本发明涉及一种基因递送载体、基因递送系统及其制备方法和应用。本发明的基因递送系统包含本发明的基因递送载体和脂质纳米颗粒；所述脂质纳米颗粒包封所述基因递送载体。现有技术暂未发现有基于脂质纳米颗粒LNP递送OTC‑circRNA基因治疗代谢紊乱疾病或病症（诸如OTCD）的相关研究，因此本发明首次构建基于LNP递送的含OTC‑circRNA药物基因的载体，其可以用于治疗代谢紊乱的疾病或病症，并在体内外水平研究其治疗的有效性和安全性，为临床上该类基因缺陷患者的治疗提供理新的方案，具有重要的应用价值。本发明的包封OTC‑circRNA的脂质纳米颗粒在体内稳定性好，安全性好，疗效持续时间长。
Absstract of: CN121129798A
本发明涉及抗菌材料技术领域，尤其涉及一种增强芦荟大黄素光动力抗菌活性的方法，包括以下步骤：S1、将共聚物干粉加入超纯水中，在室温下搅拌，得到共聚物储备液；S2、将芦荟大黄素加入无水乙醇中，溶解后加入超纯水，超声处理，得到芦荟大黄素纳米晶体的初级分散液；S3、将初级分散液置于冰浴中，在搅拌下滴加共聚物储备液，纯化后，得到芦荟大黄素纳米晶体。本发明通过构建的芦荟大黄素纳米晶体，有效解决了芦荟大黄素水溶性差、光稳定性不佳的关键瓶颈，能显著提高其光动力活性氧产率，从而对革兰氏阴性菌具有较强的杀菌作用。
Absstract of: CN121129794A
本发明公开了一种木质素‑三碘甲状腺原氨酸自组装颗粒及其制备方法与应用。所述木质素‑三碘甲状腺原氨酸复合纳米颗粒是由木质素和三碘甲状腺原氨酸共同自组装制备得到。通过实验证明：该木质素‑三碘甲状腺原氨酸复合纳米颗粒单次原位注射可增加正常饮食喂养小鼠皮下脂肪组织UCP‑1的表达、减小脂肪细胞；单次原位注射可增加短期高脂饮食喂养小鼠皮下脂肪组织UCP‑1的表达、减少脂肪组织重量、增加小鼠能量消耗、改善小鼠葡萄糖耐量；多次原位注射可改善长期高脂饮食导致的肥胖和脂肪肝。本发明提供的木质素‑三碘甲状腺原氨酸复合纳米颗粒将在治疗或缓解或改善肥胖或与肥胖相关的代谢性疾病中具有良好的应用前景。
Absstract of: JP2025020123A
To provide a composition that enables safe and efficient delivery of large molecules (e.g., polypeptides and nucleic acids) to their target tissues.SOLUTION: Provided are a cationic polymer comprising a structure of Formula (1), a method of preparing the polymer, and a composition comprising the polymer and a nucleic acid and/or polypeptide.SELECTED DRAWING: None
Absstract of: CN121130076A
本发明公开了一种GSH响应性光热化学协同的液态金属纳米复合材料的制备及其在肿瘤治疗的应用，涉及纳米生物医药材料领域。所述复合材料以镓锡合金（GaSn）为内核，依次包覆还原氧化石墨烯（RGO）中间层和二氧化锰（MnO2）外壳，形成三层核壳结构，平均粒径控制在60 nm左右。该液态金属复合纳米材料具有优异的光热转换性能及抗氧化性能。它不仅可以用于肿瘤癌症治疗，快速杀死癌症细胞，实现对肿瘤生长的有效抑制，还可以快速耗竭GSH，打破氧化还原的动态平衡，提高细胞内ROS水平。实验表明，该材料对肿瘤细胞展现出显著的抑制效果，且兼具良好的生物相容性和调控释放特性，为实体瘤的精准协同治疗提供了新策略。
Absstract of: CN121130099A
本发明涉及肿瘤治疗药物技术领域，具体涉及环己二胺修饰纳米铂在制备肿瘤可视化治疗药物中的应用。所述环己二胺修饰纳米铂的制备方法为：将氯铂酸还原，制备铂纳米粒；加入环己二胺，反复超声，即得。本发明所述环己二胺修饰纳米铂药物经静脉注射后，具有类似传统小分子铂类药物的肿瘤细胞毒效果，在近红外光照射下，具有进一步增强的肿瘤细胞杀伤作用。同时，本发明提供的环己二胺修饰纳米铂药物还可在近红外光声成像设备的辅助下，实现肿瘤的可视化治疗，具有极大的临床推广应用价值。
Absstract of: CN121129976A
本申请公开了一种抗疲劳提高免疫力液体功能香氛及其制备方法，涉及功能性香氛技术领域，其原料按重量份包括10‑30份复合精油纳米微胶囊、30‑50份基础油、0.1‑0.5份防腐剂、20‑40份溶剂；所述复合精油纳米微胶囊以复合精油为芯材，以改性大豆分离蛋白和改性壳聚糖为壁材；所述复合精油按质量百分比包括10‑14%白芷精油、8‑12%薄荷精油、12‑16%迷迭香精油、8‑12%柠檬精油、4‑8%桉树油、7‑11%山茶树精油、10‑14%肉豆蔻精油、10‑14%红景天精油、8‑12%人参精油、2.5‑3.5%维生素E油、1.5‑6.5%橙花精油。本申请提供的液体功能香氛具有优异的抗氧化、抗疲劳性能，且香氛性能稳定，能在较长的保质期内仍能保持良好的功效。
Absstract of: CN121129795A
本发明涉及生物医药领域，尤其涉及一种基于豆粕的重组脂质纳米粒的制备方法，该方法包括：豆粕原料预处理，提高脂质提取率，确定提取工艺步骤，从大豆粕中提取脂质，采用响应面法和Box‑Behnken设计优化从大豆粕中提取脂质的具体工艺参数，提取后的豆粕脂质制备重构脂质纳米粒，取多种细胞培养分析，量化重构脂质纳米粒效果，进行载药能力评估，优化载药量和包封率随载药比例，利用现有技术评价生物膜相关性。本发明通过开发了源自大豆粕的重构脂质纳米粒，进行药物递送，优化脂质提取工艺，重构脂质纳米粒增强了细胞摄取能力，并对所载药物表现出显著的增效作用，通过重构脂质纳米粒载药能力评估，可以减少药物浪费，保证疗效，优化给药剂量。
Absstract of: CN121135600A
本发明提供了一种可电离脂质化合物及其应用。本发明的可电离脂质化合物具有式I所示的结构，该化合物可用于核酸递送。
Absstract of: CN121129892A
本发明提供砷烯纳米制剂和/或β‑榄香烯在制备治疗脑部肿瘤产品中的应用，属于生物技术领域。本发明将砷烯纳米制剂和/或β‑榄香烯应用到脑胶质瘤和肺癌脑转移瘤模型小鼠中，能够有效杀伤肿瘤细胞，抑制肿瘤转移，并激活体内免疫反应，促进树突细胞的成熟，有效激活NK细胞、CD8+ T细胞，抑瘤细胞因子分泌量增加。同时，β‑榄香烯有效降低了砷烯纳米制剂在体内累积导致的心脏毒性。
Absstract of: CN121136990A
本发明公开一种编码胰岛素样生长因子2mRNA结合蛋白3多肽的多核苷酸、mRNA、药物组合物及其用途、含该可离子化脂质的药物组合物及其用途，属于生物技术领域；本发明提出了一种多核苷酸、mRNA、及包含其的组合物、脂质纳米颗粒，采用包含了本发明多核苷酸、mRNA的组合物、脂质纳米颗粒，具有预防和治疗肿瘤的显著效果。
Absstract of: MX2025006274A
This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.
Nº publicación: JP2025540675A 16/12/2025
Applicant:
ザトラスティーズオブザユニバーシティオブペンシルバニア
Absstract of: CN120641080A
Compositions and methods for the control and treatment of obesity, metabolic disorders, nausea and vomiting using ODN peptides and synthetic derivatives thereof are disclosed.
BOPI
Electronic site
